PMID- 25637428 OWN - NLM STAT- MEDLINE DCOM- 20160129 LR - 20150313 IS - 1773-0449 (Electronic) IS - 1156-5233 (Linking) VI - 25 IP - 1 DP - 2015 Mar TI - A diterpenoid taxodone from Metasequoia glyptostroboides with antimycotic potential against clinical isolates of Candida species. PG - e31-8 LID - S1156-5233(14)00280-7 [pii] LID - 10.1016/j.mycmed.2014.10.017 [doi] AB - OBJECTIVE: The increasing importance of clinical isolates of Candida species and emerging resistance of Candida species to current synthetic antifungal agents have stimulated the search for safer and more effective alternative drugs from natural sources. This study was directed towards exploring the antimycotic potential of a diterpenoid compound taxodone isolated from Metasequoia glyptostroboides against pathogenic isolates of Candida species. MATERIALS AND METHODS: Antimycotic efficacy of taxodone was evaluated by disc diffusion assay, determination of minimum inhibitory (MIC) and minimum fungicidal (MFC) concentrations, and cell viability assay. To confirm a partial antimycotic mode of action of taxodone, the efficacy of taxodone was determined by measuring the release of 260 nm absorbing materials from the selected Candida species as compared to control. RESULTS: The taxodone at the concentration of 400 mug/disc displayed potential antimycotic effect against the tested clinical and pathogenic isolates of Candida species as diameters of zones of inhibitions, which were found in the range of 11 +/- 0.0 to 12.6 +/- 0.5mm. The MIC and MFC values of taxodone against the tested clinical isolates were found in the range of 250 to 1000 and 500 to 2000mu g/mL, respectively. On the other hand, the MIC and MFC values of positive control (amphotericin B) against the tested Candida isolates were found in the range of 62.5 to 250 and 500 to 2000 mug/mL. On the viable counts of the tested fungal isolates, the taxodone exerted significant antimycotic effect. Elaborative study of partial mode of action conducted onto the release of 260nm materials (DNA and RNA) revealed potential detrimental effect of taxodone on the membrane integrity of the tested pathogens at MIC concentration. CONCLUSION: With respect to the antimycotic effect of taxodone against pathogenic and clinical isolates of Candida species, it might be confirmed that bioactive compound taxodone present in M. glyptostroboides holds therapeutic value of medicinal significance. CI - Copyright (c) 2014 Elsevier Masson SAS. All rights reserved. FAU - Bajpai, V K AU - Bajpai VK AD - Department of Applied Microbiology and Biotechnology, Yeungnam University, Gyeongsan, Gyeongbuk 712-749, Republic of Korea. FAU - Park, Y-H AU - Park YH AD - Department of Applied Microbiology and Biotechnology, Yeungnam University, Gyeongsan, Gyeongbuk 712-749, Republic of Korea. Electronic address: peter@ynu.ac.kr. FAU - Kang, S C AU - Kang SC AD - Department of Biotechnology, Daegu University, Gyeongsan, Gyeongbuk 712-714, Republic of Korea. Electronic address: sckang@daegu.ac.kr. LA - eng PT - Journal Article DEP - 20141104 PL - France TA - J Mycol Med JT - Journal de mycologie medicale JID - 9425651 RN - 0 (Antifungal Agents) RN - 0 (Diterpenes) RN - 0 (taxodone) RN - 7XU7A7DROE (Amphotericin B) SB - IM MH - Amphotericin B/pharmacology MH - *Antifungal Agents/isolation & purification/pharmacology/therapeutic use MH - Candida/*drug effects MH - Candidiasis/drug therapy/microbiology MH - Cupressaceae/*chemistry MH - *Diterpenes/isolation & purification/pharmacology/therapeutic use MH - Humans MH - Microbial Sensitivity Tests OTO - NOTNLM OT - Antimycotic potential OT - Candida sp. OT - Candida species OT - Clinical isolates OT - Isolats cliniques OT - Metasequoia glyptostroboides OT - Potentiel antifongique OT - Taxodone EDAT- 2015/02/01 06:00 MHDA- 2016/01/30 06:00 CRDT- 2015/02/01 06:00 PHST- 2014/07/18 00:00 [received] PHST- 2014/09/23 00:00 [revised] PHST- 2014/10/29 00:00 [accepted] PHST- 2015/02/01 06:00 [entrez] PHST- 2015/02/01 06:00 [pubmed] PHST- 2016/01/30 06:00 [medline] AID - S1156-5233(14)00280-7 [pii] AID - 10.1016/j.mycmed.2014.10.017 [doi] PST - ppublish SO - J Mycol Med. 2015 Mar;25(1):e31-8. doi: 10.1016/j.mycmed.2014.10.017. Epub 2014 Nov 4.